Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

e adequate protection. In contrast, Inovio's vaccine is designed to broadly protect against multiple known and unknown strains within a subtype such as H1N1 – the unanswered question has been whether or not such a universal vaccine could broadly achieve protective levels of immune responses against unmatched flu strains and whether it could provide response rates (i.e. the number of subjects achieving protective immune response levels) equivalent to a conventional vaccine when tested against the virus strain matching that vaccine. This is the first demonstration of a SynCon® influenza vaccine achieving protective equivalency relative to a conventional seasonal vaccine while uniquely possessing the advantage of generating protective immune responses against diverse unmatched strains, which was also shown in this study as well as a prior study focused on H5N1.

Inovio and its partner VGX International, Inc. will move Inovio's hepatitis C (HCV) DNA vaccine into a phase I/IIa clinical trial by the end of 2013. The preclinical research, which demonstrated for the first time that a multi-antigen (NS3/4A, NS4B, and NS5A) SynCon® HCV vaccine can generate robust T-cell responses in the liver, an organ known to suppress T-cell activity, appeared in the peer-reviewed journal Plos One in an article entitled: "Induction of Intrahepatic HCV NS4B, NS5A and NS5B Specific Cellular Immune Responses following Peripheral Immunization." VGX International is funding all preclinical and clinical development.

Subsequent to the quarter, our collaborator ChronTech Pharma AB announced that preliminary results from their open label phase II clinical study of their ChronVac-C® (NS3/4A only) therapeutic HCV vaccine administered with Inovio's MedPulserTM-DDS electroporation device followed by a drug regimen (ribavirin + PEG-interferon-a) in chronic HCV positive subjects did not to date show a statistical
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... zinc oxide (ZnO) are among the most technologically ... in optoelectronic elements such as blue lasers (hence ... also finds many uses in optoelectronics and sensors. ... made of these materials have shown a plethora ...
... Cell Assurance, Inc. (Pink Sheets: SCLZ) announced ... the Alexandria Innovation Center in Jupiter, Florida to open its ... Assurance represents an integral step for the Company to begin ... with developing potential cellular treatment protocols, stem cell based IP, ...
... developing a new class of "plasmonic metamaterials" as ... ultrapowerful microscopes and computers, improved solar cells, and ... could make possible "nanophotonic" devices for numerous applications, ... and computer engineering at Purdue University. Unlike ...
Cached Biology Technology:Nanowires exhibit giant piezoelectricity 2Nanowires exhibit giant piezoelectricity 3Stem Cell Assurance to Open New Laboratory Facility in Jupiter, Florida 2New materials may bring advanced optical technologies, cloaking 2
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... Illinois at Champaign-Urbana have found that people employed in ... Uganda are exchanging gastrointestinal bacteria ?specifically Escherichia coli ?with ... strains migrating to chimps are resistant to antibiotics used ... appear in the April 2007 issue of Biological Conservation ...
... Researchers from Biotech Research & Innovation Centre (BRIC) at University ... regulate the function of stem cells. The results are published ... including human beings, consist of a number of specialised cell ... cell; the embryonic stem cell. Stem cells can develop into ...
... for improved study of hepatitis C virus by devising ... patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus ... by Lázaro et al, "Hepatitis C virus replication in ... the February issue of The American Journal of Pathology. ...
Cached Biology News:E. coli bacteria migrating between humans, chimps in Ugandan park 2E. coli bacteria migrating between humans, chimps in Ugandan park 3New culture method for hepatitis C virus uses primary hepatocytes and patient serum 2
... number is a new product number, ... number. If showing no availability yet, ... number (C6671) or contact customer service ... Surface area 148 cm 2 ...
... Detection System is intended for use in ... by an in-house validated in vitro nucleic ... interest. • The ... hybridization capture assay designed to detect amplified ...
... System is optimized for maximum packaging efficiencies of ... bacteriophage l vector. Using a test insert with ... arms (> 4 x 10^8 pfu/g ligated l ... is extremely easy to use; simply add up ...
BD BioCoat Laminin 150 mm Culture Dishes...
Biology Products: